Aromatase inhibitors for early breast cancer therapy: A choice of effective treatment strategies

European Journal of Surgical Oncology

Volumn 32, Issue 2, 2006, Pages 123-125

  Dixon, J M ^a   Bundred, N ^b  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

^b MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; EXEMESTANE; LETROZOLE; TAMOXIFEN;

BONE DENSITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; FRACTURE; GYNECOLOGIC DISEASE; HEART DISEASE; HUMAN; LYMPH NODE METASTASIS; MASTECTOMY; MUSCULOSKELETAL DISEASE; POSTMENOPAUSE; PREOPERATIVE CARE; PRIORITY JOURNAL; REVIEW; THROMBOEMBOLISM;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; FEMALE; HUMANS; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIALS; TIME FACTORS; TREATMENT OUTCOME;

EID: 32944454971     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejso.2005.09.015     Document Type: Review

References (17)

1. H.T. Mouridsen C. Rose A.H. Brodie I.E. Smith Challenges in the endocrine management of breast cancer Breast 12 Suppl 2 2003 S2-S19
2. J.M. Dixon Role of endocrine therapy in the neoadjuvant surgical setting Ann Surg Oncol 11 Suppl 2004 18S-23S
3. W. Eiermann S. Paepke J. et al. Appfelstaedt Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study Ann Oncol 12 2001 1527-1532
4. M.J. Ellis A. Coop B. et al. Singh Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial J Clin Oncol 19 2001 3808-3816
5. I. Smith M. Dowsett Comparison of anastrozole vs tamoxifen alone and in combination as neoadjuvant treatment of estrogen receptor-positive (ER+) operable breast cancer in postmenopausal women: The IMPACT trial Breast Cancer Res Treat 82 Suppl 1 2003 S6 [Abstract 1; and oral presentation at: Twenty-sixth annual San Antonio breast cancer symposium; December 3-6, 2003; San Antonio, TX]
6. A. Howell J. Cuzick M. Baum Results of the ATAC (Arimidex Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer Lancet 365 2005 60-62
7. B.J. Thürlimann A. Keshaviah H. et al. Mouridsen BIG 1-98: randomized double-blind phase III study to evaluate letrozole (L) vs. tamoxifen (T) as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer J Clin Oncol 23 16S 2005 6s [Abstract 511; and oral presentation at: Forty-first annual meeting of the American Society of Clinical Oncology; May 13-17, 2005; Orlando, FL]
8. R.C. Coombes E. Hall C.F. Snowdon J.M. Bliss The Intergroup Exemestane Study: A randomized trial in postmenopausal patients with early breast cancer who remain disease-free after two to three years of tamoxifen-updated survival analysis Breast Cancer Res Treat 88 Suppl 1 2004 S7 [Abstract 3; and oral presentation at: Twenty-seventh annual San Antonio breast cancer symposium; December 8-11, 2004; San Antonio, TX]
9. F. Boccardo A. Rubagotti D. Amorosa et al. Anastrozole appears to be superior to tamoxifen in women already receiving adjuvant tamoxifen treatment Breast Cancer Res Treat 82 Suppl 1 2003 S6-S7
10. R. Jakesz M. Kaufmann M. et al. Gnant Benefits of switching postmenopausal women with hormone-sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: Combined results from 3123 women enrolled in the ABCSG Trial 8 and the ARNO 95 Trial Breast Cancer Res Treat 88 Suppl 1 2004 S7 [Abstract 2; and oral presentation at: twenty-seventh annual San Antonio breast cancer symposium; December 8-11, 2004; San Antonio, TX]
11. P.E. Goss Preliminary data from ongoing adjuvant aromatase inhibitor trials Clin Cancer Res 7 Suppl 2001 4397s-4401s
12. Goss PE. NCIC CTG MA.17-final analysis of updated data-a placebo-controlled trial of letrozole following tamoxifen as adjuvant therapy in postmenopausal women with early stage breast cancer. Available at: http://www.ctg.queensu.ca/public/asco/ma17-asco-2004.pdf; 2004.
13. E.P. Winer C. Hudis H.J. et al. Burstein American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: Status report 2004 J Clin Oncol 23 2005 619-629
14. J. Houghton on behalf of the ATAC Trialists' Group Using anastrozole as initial adjuvant treatment prevents early recurrences and reduces adverse events: Updated data from the ATAC 'Arimidex' Tamoxifen, Alone or in Combination) Trial J Clin Oncol 23 16S 2005 24s [Abstract 582; and poster presentation at: Forty-first annual meeting of the American Society of Clinical Oncology; May 13-17, 2005; Orlando, FL]
15. T. Saphner D.C. Tormey R. Gray Annual hazard rates of recurrence for breast cancer after primary therapy J Clin Oncol 14 1996 2738-2746
16. R. Schiff S.A. Massarweh J. Shou L. Bharwani S.K. Mohsin C.K. Osborne Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance Clin Cancer Res 10 Pt 2 2004 331S-336S
17. M. Dowsett Origin and characteristics of adverse events in aromatase inhibition therapy for breast cancer Semin Oncol 30 Suppl 14 2003 58-69